NCT00216723已完成不适用
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,000
- 试验地点
- 2
研究概览
简要总结
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
详细描述
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment.
Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment.
This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.
研究设计
- 研究类型
- Observational
- 观察模型
- Ecologic Or Community
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria
- •Age: more than 18 years of age
排除标准
- •Unqualified patients judged by study investigator(s)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
招募中
不适用
Real-life Assessment of Abilify Maintena + Rexult in SchizophreniaSchizophrenia and Related DisordersAnxiety DepressionNCT05169268The University of Hong Kong10
已完成
4 期
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
已完成
4 期
Effect on Cognitive Function of a Treatment With AripiprazoleSchizophreniaNCT00329810Otsuka Pharmaceutical Development & Commercialization, Inc.500
已完成
不适用
Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive functioschizophreniaJPRN-UMIN000002076Kyoto University Hospital20